Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Department of Infectious Diseases, West German Centre for Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Cytotherapy. 2023 Aug;25(8):821-836. doi: 10.1016/j.jcyt.2023.03.008. Epub 2023 Apr 12.
Extracellular vesicles (EVs) harvested from conditioned media of human mesenchymal stromal cells (MSCs) suppress acute inflammation in various disease models and promote regeneration of damaged tissues. After successful treatment of a patient with acute steroid-refractory graft-versus-host disease (GVHD) using EVs prepared from conditioned media of human bone marrow-derived MSCs, this study focused on improving the MSC-EV production for clinical application.
Independent MSC-EV preparations all produced according to a standardized procedure revealed broad immunomodulatory differences. Only a proportion of the MSC-EV products applied effectively modulated immune responses in a multi-donor mixed lymphocyte reaction (mdMLR) assay. To explore the relevance of such differences in vivo, at first a mouse GVHD model was optimized.
The functional testing of selected MSC-EV preparations demonstrated that MSC-EV preparations revealing immunomodulatory capabilities in the mdMLR assay also effectively suppress GVHD symptoms in this model. In contrast, MSC-EV preparations, lacking such in vitro activities, also failed to modulate GVHD symptoms in vivo. Searching for differences of the active and inactive MSC-EV preparations, no concrete proteins or miRNAs were identified that could serve as surrogate markers.
Standardized MSC-EV production strategies may not be sufficient to warrant manufacturing of MSC-EV products with reproducible qualities. Consequently, given this functional heterogeneity, every individual MSC-EV preparation considered for the clinical application should be evaluated for its therapeutic potency before administration to patients. Here, upon comparing immunomodulating capabilities of independent MSC-EV preparations in vivo and in vitro, we found that the mdMLR assay was qualified for such analyses.
从人骨髓间充质干细胞(MSCs)的条件培养基中提取的细胞外囊泡(EVs)可抑制各种疾病模型中的急性炎症,并促进受损组织的再生。在用来源于人骨髓来源的 MSC 的条件培养基制备的 EV 成功治疗了一名急性类固醇难治性移植物抗宿主病(GVHD)患者后,本研究专注于提高 MSC-EV 的生产,以用于临床应用。
根据标准化程序独立制备的 MSC-EV 制剂均显示出广泛的免疫调节差异。只有一部分 MSC-EV 产品在多供体混合淋巴细胞反应(mdMLR)测定中有效调节了免疫反应。为了探索体内这些差异的相关性,首先优化了小鼠 GVHD 模型。
对选定的 MSC-EV 制剂进行的功能测试表明,在 mdMLR 测定中具有免疫调节能力的 MSC-EV 制剂也可有效抑制该模型中的 GVHD 症状。相比之下,缺乏这种体外活性的 MSC-EV 制剂也未能调节体内 GVHD 症状。在寻找有活性和无活性的 MSC-EV 制剂的差异时,没有发现可以作为替代标志物的具体蛋白质或 miRNA。
标准化的 MSC-EV 生产策略可能不足以保证具有可重复质量的 MSC-EV 产品的制造。因此,鉴于这种功能异质性,在将每个考虑用于临床应用的 MSC-EV 制剂给予患者之前,都应评估其治疗效力。在这里,通过比较体内和体外独立 MSC-EV 制剂的免疫调节能力,我们发现 mdMLR 测定适合进行此类分析。